Cargando…
Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation
In recent years it has been recognized that clinical translation of novel therapeutic strategies for patients with adrenocortical carcinoma (ACC) often fails. These disappointing results indicate that the currently utilized tumor models only poorly reflect relevant pathophysiology and, thereby, do n...
Autores principales: | Hantel, Constanze, Shapiro, Igor, Poli, Giada, Chiapponi, Costanza, Bidlingmaier, Martin, Reincke, Martin, Luconi, Michaela, Jung, Sara, Beuschlein, Felix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346714/ https://www.ncbi.nlm.nih.gov/pubmed/27764813 http://dx.doi.org/10.18632/oncotarget.12685 |
Ejemplares similares
-
Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021) -
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022) -
Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids
por: Langer, Carolin, et al.
Publicado: (2022) -
Metformin as a new anti-cancer drug in adrenocortical carcinoma
por: Poli, Giada, et al.
Publicado: (2016) -
New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer
por: Salvianti, Francesca, et al.
Publicado: (2017)